Reset filters
13 November 2024

Webinar presentations: The PAH microenvironment: lessons learned from tumor microenvironment mechano-induced cell metabolism changes; Identification of arterial and venous morphologic markers in pulmonary arterial hypertension using CT imaging; The keto diet as treatment for pulmonary hypertension associated with obesity; Endothelial transdifferential from exacerbated inflammatory signaling in BMP9 in lung endothelium; The role of pericytes in the pathophysiology of pulmonary arterial hypertension

Members Only
12 November 2024

Leveraging the potential of virtual platforms in the post-COVID-19 era, the Infection and Pulmonary Vascular Diseases Consortium (iPVDc), with the support of the Pulmonary Vascular Research Institute (PVRI), launched a globally accessible educational program to highlight top-notch research on inflammation and infectious diseases affecting the lung vasculature.

Pulmonary Circulation
8 November 2024

Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.

Pulmonary Circulation
7 November 2024

Current risk assessment of pulmonary embolism (PE) stratifies patients based on hemodynamic stability, clinical parameters of severity, right ventricular dysfunction and cardiac injury but fails to integrate a wide variety of comorbid conditions. The Charlson Comorbidity Index (CCI) predicts mortality based on patients' diseases and provides a system to quantify disease burden. 

Pulmonary Circulation
6 November 2024

The discrimination between pre and postcapillary exercise-induced pulmonary hypertension relies on accurate measurement of pulmonary capillary wedge pressure, which can be unreliable. We found that exercise pulmonary artery compliance and right atrial pressure (AUC 0.88, 0.89, respectively) can differentiate subtypes of exercise-induced pulmonary hypertension in the absence of wedge pressure.

Pulmonary Circulation
5 November 2024

Part of the 'Hypoxia in pulmonary vascular research – altitude and beyond' webinar series by the High Altitude Task Force, who raise awareness and understanding of PH linked to high altitude and organise scientific conferences in regions affected by high altitudes.

IDDI Workstream or Task Force Learning
24 October 2024

In this Community Call, we discussed:

  • Deep phenotyping of unaffected carriers of pathogenic BMPR2 variants screened for pulmonary arterial hypertension
  • Pulmonary hypertension induced by right pulmonary artery occlusion: hemodynamic consequences of Bmpr2 mutation
PVRI Community Calls